These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 27469018)

  • 21. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension.
    Channick RN; Olschewski H; Seeger W; Staub T; Voswinckel R; Rubin LJ
    J Am Coll Cardiol; 2006 Oct; 48(7):1433-7. PubMed ID: 17010807
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rapid Inpatient Titration of Intravenous Treprostinil for Pulmonary Arterial Hypertension: Safe and Tolerable.
    El-Kersh K; Ruf KM; Smith JS
    Am J Ther; 2018; 25(2):e213-e217. PubMed ID: 27003321
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
    McLaughlin VV; Benza RL; Rubin LJ; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubenfire M; Seeger W
    J Am Coll Cardiol; 2010 May; 55(18):1915-22. PubMed ID: 20430262
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term experience after transition from parenteral prostanoids to oral agents in patients with pulmonary hypertension.
    Diaz-Guzman E; Heresi GA; Dweik RA; Minai OA
    Respir Med; 2008 May; 102(5):681-9. PubMed ID: 18280130
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan.
    Benza RL; Rayburn BK; Tallaj JA; Pamboukian SV; Bourge RC
    Chest; 2008 Jul; 134(1):139-45. PubMed ID: 18403673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transition from treprostinil to selexipag in patients with pulmonary arterial hypertension: Case series.
    Fanous SM; Janmohamed M
    Am J Health Syst Pharm; 2018 Dec; 75(23):1877-1881. PubMed ID: 30301721
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treprostinil for the treatment of pulmonary arterial hypertension.
    Torres F; Rubin LJ
    Expert Rev Cardiovasc Ther; 2013 Jan; 11(1):13-25. PubMed ID: 23259441
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety, efficacy and Management of subcutaneous treprostinil infusions in the treatment of severe pediatric pulmonary hypertension.
    Levy M; Del Cerro MJ; Nadaud S; Vadlamudi K; Colgazier E; Fineman J; Bonnet D; Adatia I
    Int J Cardiol; 2018 Aug; 264():153-157. PubMed ID: 29650343
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.
    Frost A; Janmohamed M; Fritz JS; McConnell JW; Poch D; Fortin TA; Miller CE; Chin KM; Fisher M; Eggert M; McEvoy C; Benza RL; Farber HW; Kim NH; Pfister T; Shiraga Y; McLaughlin V
    J Heart Lung Transplant; 2019 Jan; 38(1):43-50. PubMed ID: 30391194
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension.
    Lang I; Gomez-Sanchez M; Kneussl M; Naeije R; Escribano P; Skoro-Sajer N; Vachiery JL
    Chest; 2006 Jun; 129(6):1636-43. PubMed ID: 16778286
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of Pulmonary Capillary Wedge Pressure on Long-Term Mortality in Patients With Pulmonary Arterial Hypertension Treated With Parenteral Trepostinil.
    Patel JK; Rao Y; Strachan P
    Heart Lung Circ; 2018 Feb; 27(2):183-189. PubMed ID: 28400191
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial.
    Tapson VF; Gomberg-Maitland M; McLaughlin VV; Benza RL; Widlitz AC; Krichman A; Barst RJ
    Chest; 2006 Mar; 129(3):683-8. PubMed ID: 16537868
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension.
    McLaughlin VV; Gaine SP; Barst RJ; Oudiz RJ; Bourge RC; Frost A; Robbins IM; Tapson VF; McGoon MD; Badesch DB; Sigman J; Roscigno R; Blackburn SD; Arneson C; Rubin LJ; Rich S;
    J Cardiovasc Pharmacol; 2003 Feb; 41(2):293-9. PubMed ID: 12548091
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Delivery of intravenous treprostinil at low infusion rates using a miniaturized infusion pump in patients with pulmonary arterial hypertension.
    Tapson VF; McLaughlin VV; Gomberg-Maitland M; Widlitz AC; Krichman AD; Laliberte KJ; Zaccardelli DS; Barst RJ
    J Vasc Access; 2006; 7(3):112-7. PubMed ID: 17019662
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transition from intravenous or subcutaneous prostacyclin therapy to inhaled treprostinil in patients with pulmonary arterial hypertension: a retrospective case series.
    Enderby CY; Soukup M; Al Omari M; Zeiger T; Burger C
    J Clin Pharm Ther; 2014 Oct; 39(5):496-500. PubMed ID: 24806480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension.
    Melnick L; Barst RJ; Rowan CA; Kerstein D; Rosenzweig EB
    Am J Cardiol; 2010 May; 105(10):1485-9. PubMed ID: 20451700
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transition of stable pediatric patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil.
    Ivy DD; Claussen L; Doran A
    Am J Cardiol; 2007 Mar; 99(5):696-8. PubMed ID: 17317374
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension.
    Sadushi-Koliçi R; Skoro-Sajer N; Zimmer D; Bonderman D; Schemper M; Klepetko W; Glatz J; Jakowitsch J; Lang IM
    J Heart Lung Transplant; 2012 Jul; 31(7):735-43. PubMed ID: 22480725
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transition protocol from subcutaneous treprostinil to intravenous epoprostenol in deteriorating patients with pulmonary arterial hypertension.
    Mouratoglou SA; Patsiala A; Feloukidis C; Karvounis H; Giannakoulas G
    Int J Cardiol; 2020 May; 306():187-189. PubMed ID: 32115272
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transition of Intravenous Treprostinil to Oral Therapy in a Patient with Functional Class IV Chronic Thromboembolic Pulmonary Hypertension.
    Thurber KM; Williams BM; Bates RE; Frantz RP
    Pharmacotherapy; 2017 Aug; 37(8):e76-e81. PubMed ID: 28513869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.